Detalhe da pesquisa
1.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother
; 76(12): 3286-3295, 2021 11 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34450619
2.
Pelargonium sidoides root extract for the treatment of acute cough due to lower respiratory tract infection in adults: a feasibility double-blind, placebo-controlled randomised trial.
BMC Complement Med Ther
; 21(1): 48, 2021 Jan 29.
Artigo
Inglês
| MEDLINE | ID: mdl-33514367
3.
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial.
Trials
; 21(1): 544, 2020 Jun 19.
Artigo
Inglês
| MEDLINE | ID: mdl-32560744
4.
HATRIC: a study of Pelargonium sidoides root extract EPs®7630 (Kaloba®) for the treatment of acute cough due to lower respiratory tract infection in adults-study protocol for a double blind, placebo-controlled randomised feasibility trial.
Pilot Feasibility Stud
; 5: 98, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31384480